Literature DB >> 8959485

Liposomal doxorubicin.

P G Tardi1, N L Boman, P R Cullis.   

Abstract

Doxorubicin is a potent antineoplastic agent with activity against numerous human cancers. Encapsulation of doxorubicin inside a liposome alters bioavailability, biodistribution and thus its biological activity significantly. The physical properties of the liposome (size, lipid components and lipid dose) play a major role in determining drug retention and pharmacokinetics. The therapeutic benefits of liposomal doxorubicin will therefore depend on these physical characteristics. Here we review the toxicity and efficacy of liposomal doxorubicin determined for various liposome compositions (size, lipid composition and drug-to-lipid ratio). These physical properties can be independently varied using the transmembrane pH gradient-dependent drug encapsulation procedure. The results show that the toxicity of the formulation is related to drug retention in the circulation. The antitumor activity is more sensitive to the size of the liposomes. By optimizing these parameters, liposomal doxorubicin formulations can be optimized for improved therapeutic activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959485     DOI: 10.3109/10611869609015970

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  28 in total

1.  Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs.

Authors:  D N Waterhouse; N Dos Santos; L D Mayer; M B Bally
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Nanospheres encapsulating anti-leishmanial drugs for their specific macrophage targeting, reduced toxicity, and deliberate intracellular release.

Authors:  Anil Kumar Shukla; Sanjukta Patra; Vikash Kumar Dubey
Journal:  Vector Borne Zoonotic Dis       Date:  2012-08-27       Impact factor: 2.133

Review 3.  Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation.

Authors:  Xiangsheng Liu; Ivanna Tang; Zev A Wainberg; Huan Meng
Journal:  Small       Date:  2020-05-14       Impact factor: 13.281

Review 4.  A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Authors:  D N Waterhouse; P G Tardi; L D Mayer; M B Bally
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of Leishmaniasis.

Authors:  Anil Kumar Shukla; Sanjukta Patra; Vikash Kumar Dubey
Journal:  Mol Cell Biochem       Date:  2011-02-26       Impact factor: 3.396

Review 6.  Late Cardiotoxicity: Issues for Childhood Cancer Survivors.

Authors:  Jyothsna Akam-Venkata; Vivian I Franco; Steven E Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

Review 7.  Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Authors:  Danielle Harake; Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Future Cardiol       Date:  2012-07

8.  Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence.

Authors:  Hee Seung Kim; Irving W Wainer
Journal:  J Pharm Biomed Anal       Date:  2009-06-21       Impact factor: 3.935

9.  Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity.

Authors:  Peng Guo; Jin-Oh You; Jiang Yang; Marsha A Moses; Debra T Auguste
Journal:  Biomaterials       Date:  2012-08-09       Impact factor: 12.479

Review 10.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Authors:  Atiar M Rahman; Syed Wamique Yusuf; Michael S Ewer
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.